Harbor Capital Advisors Inc. Acquires 20,891 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Harbor Capital Advisors Inc. increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 647.8% during the second quarter, Holdings Channel.com reports. The firm owned 24,116 shares of the biopharmaceutical company’s stock after buying an additional 20,891 shares during the period. Harbor Capital Advisors Inc.’s holdings in Xenon Pharmaceuticals were worth $940,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XENE. Tower Research Capital LLC TRC boosted its stake in shares of Xenon Pharmaceuticals by 414.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 817 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Xenon Pharmaceuticals by 51.2% during the fourth quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 381 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $91,000. 17 Capital Partners LLC bought a new position in shares of Xenon Pharmaceuticals during the first quarter valued at approximately $122,000. Finally, EntryPoint Capital LLC bought a new position in shares of Xenon Pharmaceuticals during the first quarter valued at approximately $195,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Trading Down 2.9 %

Shares of NASDAQ XENE traded down $1.22 during midday trading on Wednesday, reaching $40.78. The company had a trading volume of 156,096 shares, compared to its average volume of 405,588. The business’s 50-day simple moving average is $39.60 and its 200 day simple moving average is $42.35. The stock has a market cap of $3.08 billion, a P/E ratio of -15.50 and a beta of 1.26. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.07. The business had revenue of $1.00 million for the quarter. During the same period in the previous year, the business posted ($0.63) earnings per share. Xenon Pharmaceuticals’s revenue was up .0% compared to the same quarter last year. Analysts predict that Xenon Pharmaceuticals Inc. will post -2.98 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on XENE shares. Needham & Company LLC restated a “buy” rating and issued a $62.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, May 10th. Citigroup lowered their target price on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 10th. Wedbush lowered their target price on shares of Xenon Pharmaceuticals from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.11.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.